KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $55.0 million.

  • Adaptive Biotechnologies' Cash & Equivalents rose 4450.69% to $55.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.0 million, marking a year-over-year increase of 4450.69%. This contributed to the annual value of $47.9 million for FY2024, which is 2634.94% down from last year.
  • Latest data reveals that Adaptive Biotechnologies reported Cash & Equivalents of $55.0 million as of Q3 2025, which was up 4450.69% from $43.2 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Cash & Equivalents high stood at $217.6 million for Q3 2022, and its period low was $38.1 million during Q3 2024.
  • Its 5-year average for Cash & Equivalents is $96.9 million, with a median of $88.7 million in 2023.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 7537.58% in 2021, then surged by 7773.71% in 2022.
  • Over the past 5 years, Adaptive Biotechnologies' Cash & Equivalents (Quarter) stood at $139.1 million in 2021, then crashed by 35.26% to $90.0 million in 2022, then decreased by 27.73% to $65.1 million in 2023, then dropped by 26.35% to $47.9 million in 2024, then grew by 14.85% to $55.0 million in 2025.
  • Its Cash & Equivalents was $55.0 million in Q3 2025, compared to $43.2 million in Q2 2025 and $50.6 million in Q1 2025.